Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial

• Main Authors: Olivier Godeaux (Author), Martina Kovac (Author), Daniel Shu (Author), Katrijn Grupping (Author), Laura Campora (Author), Martine Douha (Author), Thomas C. Heineman (Author), Himal Lal (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented history of HZ. Participants (stratified by age: 50-59, 60...